ASCLS eNewsBytes

• Extrapulmonary Nontuberculous Mycobacteria Infection: The New-Age Neglected Infectious Disease March 24, 2025
  Nontuberculous mycobacteria, atypical mycobacteria, cause pulmonary disease and extrapulmonary infections in immunocompromised populations.
• Predictive Model Using Systemic Inflammation Markers to Assess Neoadjuvant Chemotherapy Efficacy in Breast Cancer March 24, 2025
  This study explores the predictive and prognostic value of systemic inflammation markers and clinicopathological characteristics in breast cancer patients receiving neoadjuvant chemotherapy, constructing a pCR prediction model.
• Stem Cell Study Shows Lactic Acid Bacteria May Inhibit Cervical Cancer Development March 24, 2025
  Research team reveals human cervical stem cell identity and differentiation process, showing lactic acid bacteria can inhibit cervical cancer development, providing new insights into cancer prevention.
• FDA Approves Johnson & Johnson's Tremfya to Treat Crohn's Disease March 24, 2025
  J&J has received FDA approval for Tremfya, an interleukin 23 inhibitor, to treat Crohn's disease in adults, offering both subcutaneous and intravenous induction options.
• Four Breakthrough Studies Could Revolutionize Tuberculosis Treatment March 24, 2025
  Tuberculosis cases in the U.S. are increasing, causing lung damage and lethal if untreated. Researchers have developed a faster method using fluorescence to label the iron-transporter protein in saliva samples.